Current role of allogeneic stem cell transplantation in follicular lymphoma

Farina, Lucia; Corradini, Paolo

doi:10.3324/haematol.11468

Cited by 1 publication

(4 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…AlloSCT represents an effective treatment for relapsed and refractory FL with 5-years OS ranging from 50–80% 16. Historical studies that compared PFS curves of patients who received ASCT or alloSCT reported a statistically significant advantage for allografted patients.…”

Section: Allogeneic Stem Cell Transplantationmentioning

confidence: 99%

“…In order to extend the fraction of eligible FL patients and to reduce the TRM, different less toxic and more feasible conditioning regimens and transplant strategies have been explored. In the last twenty years, the most important change in transplant approach has been represented by the introduction of reduced intensity conditioning (RIC) regimens which are associated with a reduced TRM without a loss of efficacy provided by the GVL effect 16,17,79. Thanks to these qualities, RIC alloSCT extended the application of allotransplant to a larger rate of FL patients that were historically considered ineligible, including also patients older than 60 years old.…”

Section: Allogeneic Stem Cell Transplantationmentioning

confidence: 99%

“…Bone marrow transplant (BMT) has been widely investigated to achieve a better response and improve the survival in FL 16–18. Autologous stem cell transplantation (ASCT) has represented one of the main treatment for relapsed FL thanks to the ability of high-dose chemotherapy to overcome the lymphoma resistance and refractoriness.…”

Section: Introductionmentioning

confidence: 99%

“…In the last years, thanks to the novel less toxic conditioning regimens available and to the significant improvement in supportive cares, the proportion of FL patients potentially eligible to ASCT and/or alloSCT has progressively expanded. Today these procedures are feasible up till the age of 65–70 years 16, 17…”

Section: Introductionmentioning

confidence: 99%

See 3 more Smart Citations

The Role of Autologous and Allogeneic Stem Cell Transplantation in Follicular Lymphoma in the New Drugs Era.

Maura¹,

Farina²,

Corradini³

2016

Mediterr J Hematol Infect Dis

View full text Add to dashboard Cite

Follicular lymphoma (FL) is the second most common histotype of non-Hodgkin’s lymphoma, and it is generally characterized by a heterogeneous clinical course. Despite recent therapeutic and diagnostic improvements, a significant fraction of FL patients still relapsed. In younger and/or fit FL relapsed patients bone marrow transplant (BMT) has represented the main salvage therapy for many years. Thanks to the ability of high-dose chemotherapy to overcome the lymphoma resistance and refractoriness, autologous stem cell transplantation (ASCT) can achieve a high complete remission rate (CR) and favorable outcome regarding progression-free survival (PFS) and overall survival (OS). Allogeneic stem cell transplantation (alloSCT) combines the high dose chemotherapy effect together with the immune reaction of the donor immune system against lymphoma, the so-called ‘graft versus lymphoma’ (GVL) effect. Considering the generally higher transplant-related mortality (TRM), alloSCT is mostly indicated for FL relapsed after ASCT. During the last years, there have been a great spread of novel effective and feasible drugs Although these and future novel drugs will probably change our current approach to FL, the OS post-BMT (ASCT and alloSCT) has never been reproduced by any novel combination. In this scenario, it is important to correctly evaluate the disease status, the relapse risk and the comorbidity profile of the relapsed FL patients in order to provide the best salvage therapy and eventually transplant consolidation.

show abstract

Section: Allogeneic Stem Cell Transplantationmentioning

confidence: 99%